GLPG: Galapagos NV
About
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
Current Value
$25.901 Year Return
Current Value
$25.901 Year Return
Key Details
Market Cap
$1.76B
P/E Ratio
-11.49
1Y Stock Return
-27.61%
1Y Revenue Growth
-7.12%
Dividend Yield
0.00%
Price to Book
0.6
Strategies that include GLPG
Stock's related to GLPG
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ACCO | 41.67% | $530.35M | +7.13% | 5.27% |
| GTN | 37.86% | $433.55M | -45.83% | 7.40% |
| RCKY | 35.62% | $155.86M | -17.74% | 2.95% |
| NWN | 35.14% | $1.68B | +15.26% | 4.67% |
| TRMK | 35.07% | $2.32B | +69.09% | 2.44% |
| PRLB | 34.60% | $907.12M | +1.96% | 0.00% |
| TTEC | 34.58% | $204.76M | -76.19% | 1.39% |
| PLYM | 34.53% | $842.88M | -11.32% | 5.12% |
| BEAM | 34.41% | $2.09B | -9.52% | 0.00% |
| TDOC | 34.20% | $1.54B | -47.22% | 0.00% |
| VICR | 34.01% | $2.40B | +39.81% | 0.00% |
| WASH | 33.92% | $628.84M | +39.42% | 5.76% |
| SCL | 33.90% | $1.69B | -6.79% | 2.01% |
| SVC | 33.90% | $431.62M | -63.31% | 23.74% |
| LMND | 33.86% | $2.87B | +150.56% | 0.00% |
| RXRX | 33.71% | $1.80B | -4.13% | 0.00% |
| LASR | 33.67% | $526.43M | -2.60% | 0.00% |
| WABC | 33.65% | $1.49B | +14.56% | 3.16% |
| VRE | 33.48% | $1.70B | +35.93% | 1.29% |
| SJW | 33.34% | $1.83B | -14.15% | 2.89% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PDD | -14.64% | $163.43B | +0.29% | 0.00% |
| ROOT | -13.23% | $1.53B | +972.93% | 0.00% |
| NHTC | -11.44% | $61.83M | +0.19% | 14.81% |
| CHD | -10.09% | $27.18B | +19.50% | 1.03% |
| UVE | -9.94% | $631.63M | +36.40% | 2.86% |
| ALAR | -9.79% | $89.09M | +158.08% | 0.00% |
| GAN | -9.48% | $83.39M | +21.19% | 0.00% |
| VSTA | -8.85% | $204.94M | -39.33% | 0.00% |
| MNR | -8.40% | $1.66B | -10.71% | 15.90% |
| CPSH | -7.56% | $20.70M | -40.13% | 0.00% |
| HUSA | -7.54% | $16.69M | -11.56% | 0.00% |
| WHLM | -7.50% | $17.64M | -29.34% | 0.00% |
| MNOV | -7.47% | $93.19M | +2.15% | 0.00% |
| XGN | -7.28% | $62.26M | +127.74% | 0.00% |
| SMC | -7.12% | $383.35M | +97.26% | 0.00% |
| MATX | -6.98% | $5.07B | +59.09% | 0.86% |
| TWLO | -6.83% | $14.78B | +54.09% | 0.00% |
| UUU | -5.71% | $4.97M | -41.89% | 0.00% |
| PAYC | -5.67% | $12.12B | +21.78% | 0.69% |
| TNDM | -5.60% | $1.83B | +51.39% | 0.00% |
ETF's related to GLPG
News
Yahoo
New Phase 1/2 data support the potential of our CAR T-cell therapy candidates, GLPG5101 and GLPG5201, in addressing unmet needs for patients with poor prognoses. Our innovative decentralized cell therapy manufacturing platform delivers fresh, fit cells within a median vein-to-vein time of seven days, with potentially encouraging patient outcomes. Three abstracts, including one oral presentation for GLPG5101 in relapsed/refractory non-Hodgkin lymphoma, and a company showcase, will spotlight our c
Yahoo
Galapagos ( AMS:GLPG ) Third Quarter 2024 Results Key Financial Results Revenue: €59.8m (down 50% from 3Q 2023). Net...
Yahoo
Galapagos NV (GLPG) reports a robust cash reserve and significant advancements in its R&D pipeline, while navigating increased R&D costs and competitive market pressures.
SeekingAlpha
The following slide deck was published by Galapagos NV in conjunction with their 2024 Q3 earnings call.
SeekingAlpha
Galapagos NV (NASDAQ:GLPG) Q3 2024 Earnings Conference Call October 31, 2024 9:00 AM ETCompany ParticipantsSofie Van Gijsel - Head of IRPaul Stoffels -...
Yahoo
We are advancing our pipeline and accelerating innovation through focused execution of our Forward, Faster strategy.We are committed to addressing the high unmet needs of patients through a growing cell therapy and small molecule pipeline with breakthrough potential. This includes more than 20 programs, with four assets in clinical development across 11 indications, and more than 15 preclinical programs in oncology and immunology. We achieved a major regulatory milestone with the FDA clearance o
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.